Canada's Valeant Pharmaceuticals International Inc agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd in an all-cash deal valued at about $10.1 billion, the two companies said on Sunday. The deal for Salix, known for its irritable bowel syndrome drug Xifaxan, was approved by the boards of directors of both companies, the companies said in a news release. The companies said the deal had an enterprise value of $14.5 billion, which would include Salix's debt and any cash on hand. The deal is the largest ever for Laval, Quebec-based Valeant, which lost a takeover contest for Allergan Inc last year.
via Business News http://ift.tt/1AkGOA9
0 commentaires:
Enregistrer un commentaire